文献速递前列腺癌

68Ga-PSMA PET/CT在前列腺癌早期生化复发中的效能与预测列线图

Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.
PubMed 文献 · Eur Urol · 2018-01-19

纳入272例根治性前列腺切除术后生化复发且PSA 0.2-1ng/ml的患者,68Ga-PSMA PET/CT在PSA 0.2-0.5ng/ml组检出率55%(74/134),>0.5-1.0ng/ml组74%(102/138)。多变量分析中同期ADT和PSA值是阳性预测的最相关因素,并建立预测列线图。

要点

  • PSA 0.2-0.5ng/ml组检出率55%(74/134),>0.5-1.0ng/ml组74%(102/138)。
  • 多变量模型中同期ADT和PSA值是阳性PET/CT的最相关预测因素。
  • 建立预测列线图,可能有助于临床估计PSMA配体PET阳性 pretest 概率。

核心结论

  • 68Ga-PSMA配体PET/CT在根治性前列腺切除术后早期生化复发(PSA 0.2-1ng/ml)患者中检出率较高,同期ADT和PSA值是阳性预测的最相关因素,预测列线图可能有助于临床实践。

研究设计与样本

  • 连续纳入272例根治性前列腺切除术后生化复发且PSA 0.2-1ng/ml的患者,评估68Ga-PSMA配体PET/CT,采用单变量和多变量分析检测率与临床变量的相关性。

主要发现

  • PSA 0.2-0.5ng/ml组检出率55%(74/134),PSA >0.5-1.0ng/ml组74%(102/138)。
  • 主要复发部位为盆腔或腹膜后淋巴结转移,其次为局部复发和骨转移,低PSA亚组(>0.5-1.0ng/ml)较极低PSA亚组(0.2-0.5ng/ml)概率更高。
  • 单变量分析中,检测率随PSA值升高、原发pT≥3a、原发pN+疾病、分级组≥4、既往放疗和同期ADT显著增加。
  • 多变量logistic回归模型中,同期ADT和PSA值被确定为68Ga-PSMA配体PET/CT阳性的最相关预测因素。

关键数值与推荐

  • PSA 0.2-0.5ng/ml组检出率55%(74/134),PSA >0.5-1.0ng/ml组74%(102/138)。
  • 单变量分析中检测率显著增加的相关因素包括:PSA值升高、原发pT≥3a、原发pN+疾病、分级组≥4、既往放疗、同期ADT。
  • 多变量logistic回归模型中,同期ADT和PSA值是阳性PET/CT的最相关预测因素。

临床怎么用

  • 基于这些数据,在早期生化复发患者中也进行68Ga-PSMA配体PET/CT似乎是合理的,因为它可以调整进一步治疗决策(如局部 vs 全身治疗)。
  • 建立的预测列线图可进一步协助泌尿科医生在特定临床情况下与患者讨论使用68Ga-PSMA配体PET/CT。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Recently, 68Ga-labeled prostate-specific membrane antigen (PSMA)-ligand positron-emission tomography (PET) imaging has been shown to improve detection rates in recurrent prostate cancer (PC). However, published studies include only small patient numbers at low prostate-specific antigen (PSA) values. For this study, 272 consecutive patients with biochemical recurrence after radical prostatectomy and PSA value between 0.2 and 1ng/ml were included. The 68Ga-PSMA-ligand PET/computed tomography (CT) was evaluated, and detection rates were determined and correlated to various clinical variables using univariate and multivariable analyses. Subgroups of patients with very low (0.2-0.5ng/ml) and low (>0.5-1.0ng/ml) PSA values were analyzed. In total, lesions indicative of PC recurrence were detected in 55% (74/134) and 74% (102/138) with very low and low PSA values, respectively. Main sites of recurrence were pelvic or retroperitoneal lymph nodes metastases, followed by local recurrence and bone metastases with higher probability in the low versus very low PSA subgroup. Detection rates significantly increased with higher PSA values, primary pT≥3a, primary pN+ disease, grade group ≥4, previous radiation therapy, and concurrent androgen deprivation therapy (ADT) in univariate analysis. In a multivariable logistic regression model, concurrent ADT and PSA values were identified as most relevant predictors of positive 68Ga-PSMA-ligand PET/CT. Further, prediction nomograms were established, which may help in estimating pretest PSMA-ligand PET positivity in clinical practice. PATIENT SUMMARY: In our study, 68Ga-labeled prostate-specific membrane antigen (PSMA)-ligand positron-emission tomography (PET)/computed tomography (CT) detected recurrent disease after radical prostatectomy in 55% (74/134) and 74% (102/138) of patients with very low (0.2-0.5ng/ml) and low (>0.5-1.0ng/ml) prostate-specific antigen values, respectively. On the basis of these data, it seems reasonable to perform 68Ga-PSMA-ligand PET/CT also in patients with early biochemical recurrence, as it can tailor further therapy decisions (eg, local vs systemic treatment). The established prediction nomograms can further assist urologists in discussions on the use of 68Ga-PSMA-ligand PET/CT with their patients in specific clinical settings.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Rauscher I, Düwel C, Haller B, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. Eur Urol. 2018. PMID: 29358059. doi:10.1016/j.eururo.2018.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。